Barclays PLC Maxcyte, Inc. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Barclays PLC holds 38,609 shares of MXCT stock, worth $142,853. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,609

Previous 79,232 51.27%

Holding current value

$142,853

Previous $332,000 54.52%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.63 - $5.0 $147,461 - $203,115	-40,623 Reduced 51.27%	38,609 $151,000
Q1 2024 May 15, 2024	SELL	$3.94 - $5.38 $230,880 - $315,262	-58,599 Reduced 42.52%	79,232 $332,000
Q4 2023 Feb 15, 2024	BUY	$2.6 - $5.24 $276,291 - $556,833	106,266 Added 336.66%	137,831 $648,000
Q3 2023 Nov 07, 2023	SELL	$3.02 - $5.1 $10,144 - $17,130	-3,359 Reduced 9.62%	31,565 $98,000
Q2 2023 Aug 03, 2023	SELL	$3.69 - $5.35 $158,500 - $229,803	-42,954 Reduced 55.16%	34,924 $159,000
Q1 2023 May 04, 2023	BUY	$4.03 - $5.89 $190,542 - $278,485	47,281 Added 154.53%	77,878 $386,000
Q4 2022 Feb 13, 2023	BUY	$4.92 - $7.4 $95,334 - $143,389	19,377 Added 172.7%	30,597 $166,000
Q3 2022 Nov 03, 2022	SELL	$4.52 - $6.51 $7,105 - $10,233	-1,572 Reduced 12.29%	11,220 $72,000
Q2 2022 Aug 12, 2022	SELL	$3.59 - $6.81 $73,368 - $139,175	-20,437 Reduced 61.5%	12,792 $61,000
Q1 2022 May 16, 2022	BUY	$5.26 - $10.84 $168,525 - $347,302	32,039 Added 2692.35%	33,229 $233,000
Q4 2021 Feb 14, 2022	SELL	$8.87 - $12.94 $257 - $375	-29 Reduced 2.38%	1,190 $12,000
Q3 2021 Nov 09, 2021	BUY	$12.21 - $17.2 $14,883 - $20,966	1,219 New	1,219 $15,000

Others Institutions Holding MXCT

# of Institutions

118

Shares Held

65M

Call Options Held

600

Put Options Held

2.7K

View Full List

About MAXCYTE, INC.

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $376M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

More about MXCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account